AGEN vs. SGMO, CRIS, ZURA, CMPX, ABOS, IPHA, OPT, CHRS, INMB, and MGX
Should you be buying Agenus stock or one of its competitors? The main competitors of Agenus include Sangamo Therapeutics (SGMO), Curis (CRIS), Zura Bio (ZURA), Compass Therapeutics (CMPX), Acumen Pharmaceuticals (ABOS), Innate Pharma (IPHA), Opthea (OPT), Coherus BioSciences (CHRS), INmune Bio (INMB), and Metagenomi (MGX). These companies are all part of the "biological products, except diagnostic" industry.
Agenus (NASDAQ:AGEN) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, community ranking, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.
Agenus has a net margin of -154.88% compared to Sangamo Therapeutics' net margin of -1,749.06%. Agenus' return on equity of 0.00% beat Sangamo Therapeutics' return on equity.
In the previous week, Sangamo Therapeutics had 3 more articles in the media than Agenus. MarketBeat recorded 13 mentions for Sangamo Therapeutics and 10 mentions for Agenus. Agenus' average media sentiment score of 0.84 beat Sangamo Therapeutics' score of 0.48 indicating that Agenus is being referred to more favorably in the media.
Agenus presently has a consensus target price of $70.00, suggesting a potential upside of 544.57%. Sangamo Therapeutics has a consensus target price of $5.67, suggesting a potential upside of 772.33%. Given Sangamo Therapeutics' higher probable upside, analysts plainly believe Sangamo Therapeutics is more favorable than Agenus.
Agenus has higher earnings, but lower revenue than Sangamo Therapeutics. Agenus is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Agenus received 25 more outperform votes than Sangamo Therapeutics when rated by MarketBeat users. Likewise, 70.09% of users gave Agenus an outperform vote while only 62.71% of users gave Sangamo Therapeutics an outperform vote.
61.5% of Agenus shares are held by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are held by institutional investors. 4.8% of Agenus shares are held by company insiders. Comparatively, 2.8% of Sangamo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Agenus has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.
Summary
Agenus beats Sangamo Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Agenus News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
